Literature DB >> 17698803

How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.

Richard G Moore, Robert C Bast.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17698803     DOI： 10.1200/JCO.2007.11.9594

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.

Authors:  Emsal Pınar Topdağı Yılmaz; Yakup Kumtepe
Journal:  Eurasian J Med       Date:  2016-10

2.  Contrast-enhanced sonography depicts spontaneous ovarian cancer at early stages in a preclinical animal model.

Authors:  Animesh Barua; Pincas Bitterman; Janice M Bahr; Sanjib Basu; Eyal Sheiner; Michael J Bradaric; Dale B Hales; Judith L Luborsky; Jacques S Abramowicz
Journal:  J Ultrasound Med       Date:  2011-03       Impact factor: 2.153

Review 3.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

4.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

Authors:  Shuai Zhen; Li-Hong Bian; Li-Li Chang; Xin Gao
Journal:  Mol Clin Oncol       Date:  2014-04-16

5.  Detection of tumor-associated neoangiogenesis by Doppler ultrasonography during early-stage ovarian cancer in laying hens: a preclinical model of human spontaneous ovarian cancer.

Authors:  Animesh Barua; Pincas Bitterman; Janice M Bahr; Michael J Bradaric; Dale B Hales; Judith L Luborsky; Jacques S Abramowicz
Journal:  J Ultrasound Med       Date:  2010-02       Impact factor: 2.153

6.  Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers.

Authors:  Burton S Brodsky; Gary M Owens; Dennis J Scotti; Keith A Needham; Christina L Cool
Journal:  Am Health Drug Benefits       Date:  2017-10

7.  Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group.

Authors:  Dirk Timmerman; Lieveke Ameye; Daniela Fischerova; Elisabeth Epstein; Gian Benedetto Melis; Stefano Guerriero; Caroline Van Holsbeke; Luca Savelli; Robert Fruscio; Andrea Alberto Lissoni; Antonia Carla Testa; Joan Veldman; Ignace Vergote; Sabine Van Huffel; Tom Bourne; Lil Valentin
Journal:  BMJ       Date:  2010-12-14

8.  The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.

Authors:  Karina Biskup; Elena Iona Braicu; Jalid Sehouli; Rudolf Tauber; Véronique Blanchard
Journal:  Dis Markers       Date:  2014-08-12       Impact factor: 3.434

9.  Combined Application of Ultrasound and CT Increased Diagnostic Value in Female Patients with Pelvic Masses.

Authors:  Yan Liu; Hui Zhang; Xiaoqian Li; Guiqin Qi
Journal:  Comput Math Methods Med       Date:  2016-10-27       Impact factor: 2.238

10.  Assessment of solid components of borderline ovarian tumor and stage I carcinoma: added value of combined diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  See Hyung Kim
Journal:  Yeungnam Univ J Med       Date:  2019-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.